Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
Authors
Keywords
Sorafenib, Hepatocyte Growth Factor, Everolimus, Platelet Derive Growth Factor Receptor, Perifosine
Journal
Targeted Oncology
Volume 12, Issue 1, Pages 1-10
Publisher
Springer Nature
Online
2016-08-11
DOI
10.1007/s11523-016-0452-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
- (2016) Zeynep Firtina Karagonlar et al. CANCER SCIENCE
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
- (2016) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Development and novel therapeutics in hepatocellular carcinoma: a review
- (2016) Pravinkumar Vishwanath Ingle et al. Therapeutics and Clinical Risk Management
- Sonic hedgehog pathway inhibitor mitigates mouse hepatocellular carcinoma
- (2015) Kuo-Shyang Jeng et al. AMERICAN JOURNAL OF SURGERY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
- (2015) Kornelius Schulze et al. NATURE GENETICS
- Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers
- (2015) Lorenza Rimassa et al. TUMORI
- MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
- (2015) Xing-Shun Qi WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
- (2015) Alessandro Granito et al. Therapeutic Advances in Gastroenterology
- Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers
- (2015) Lorenza Rimassa et al. TUMORI JOURNAL
- γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model
- (2015) Kodappully Sivaraman Siveen et al. Oncotarget
- Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells
- (2014) K S Siveen et al. BRITISH JOURNAL OF CANCER
- Genomic portrait of resectable hepatocellular carcinomas: Implications ofRB1andFGF19aberrations for patient stratification
- (2014) Sung-Min Ahn et al. HEPATOLOGY
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo
- (2014) Gautam Sethi et al. Molecular Cancer
- Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
- (2014) Yasushi Totoki et al. NATURE GENETICS
- Sorafenib: from literature to clinical practice
- (2013) V. Di Marco et al. ANNALS OF ONCOLOGY
- Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
- (2013) Z. Kan et al. GENOME RESEARCH
- Identification of driver genes in hepatocellular carcinoma by exome sequencing
- (2013) Sean P. Cleary et al. HEPATOLOGY
- GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
- (2013) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Celastrol Suppresses Growth and Induces Apoptosis of Human Hepatocellular Carcinoma through the Modulation of STAT3/JAK2 Signaling Cascade In Vitro and In Vivo
- (2012) P. Rajendran et al. Cancer Prevention Research
- Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma
- (2012) Thomas Decaens et al. DIGESTIVE AND LIVER DISEASE
- Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity
- (2012) Kuen-Feng Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of acquired resistance to targeted cancer therapies
- (2012) Mark R Lackner et al. Future Oncology
- The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling
- (2012) Xin Zheng et al. GENES CHROMOSOMES & CANCER
- Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling
- (2012) Yiliang Zhang et al. HEPATOLOGY
- Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
- (2012) Justin N. Bottsford-Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- (2012) Armando Santoro et al. LANCET ONCOLOGY
- Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies
- (2012) Shubha Bagrodia et al. Pigment Cell & Melanoma Research
- Nuclear Translocation of β-Catenin during Mesenchymal Stem Cells Differentiation into Hepatocytes Is Associated with a Tumoral Phenotype
- (2012) Carmen Herencia et al. PLoS One
- Hepatitis C virus to hepatocellular carcinoma
- (2012) Shah Jahan et al. Infectious Agents and Cancer
- Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
- (2011) Andrew X. Zhu et al. CANCER
- Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
- (2011) Qian Zhou et al. Future Oncology
- Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
- (2011) K.-F. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3
- (2011) W.-T. Tai et al. MOLECULAR CANCER THERAPEUTICS
- Targeting Cell Signaling and Apoptotic Pathways by Dietary Agents: Role in the Prevention and Treatment of Cancer
- (2011) Muthu Shanmugam et al. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
- Association of TP53 Mutations With Stem Cell-Like Gene Expression and Survival of Patients With Hepatocellular Carcinoma
- (2010) Hyun Goo Woo et al. GASTROENTEROLOGY
- IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
- (2010) Victoria Tovar et al. JOURNAL OF HEPATOLOGY
- Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
- (2009) Hung Huynh et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
- (2008) Augusto Villanueva et al. GASTROENTEROLOGY
- Molecular targeted therapies in hepatocellular carcinoma
- (2008) Josep M. Llovet et al. HEPATOLOGY
- To kill a tumor cell: the potential of proapoptotic receptor agonists
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases
- (2008) R. Kumar et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now